Optimizing Humana Skyrizi Prior Authorization Workflows

Efficiently managing Humana Skyrizi prior authorization is critical for patient access to this IL-23 inhibitor and for revenue cycle integrity.

Specialty medications like Skyrizi (risankizumab) often require intricate prior authorization processes. For revenue cycle directors and prior authorization coordinators, understanding Humana's specific requirements and submission channels is key to minimizing delays and denials, ensuring timely patient care.

Understanding Skyrizi (Risankizumab) and its Prior Authorization Context

Skyrizi, or risankizumab, is an IL-23 inhibitor manufactured by AbbVie, indicated for conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. As a high-cost specialty medication, it typically falls under a payer's medical or pharmacy benefit and requires prior authorization to ensure medical necessity and appropriate utilization.

Humana's Prior Authorization Channels for Specialty Medications

For medical benefit specialty drugs like Skyrizi, Humana primarily routes prior authorization requests through Availity Essentials, its designated provider portal. This platform facilitates PA initiation, eligibility verification, and document submission. X12 278 transactions are also supported via clearinghouses, offering an electronic submission pathway for many impacted procedures.

Key Humana PA Submission Pathways for Risankizumab

**Availity Essentials Portal**: Primary channel for medical benefit prior authorizations, including specialty drugs.
**X12 278 Transactions**: Electronic submission via clearinghouses for medical benefit services.
**CenterWell Specialty Pharmacy**: Handles pharmacy benefit specialty injectables and complex medications.
**CoverMyMeds / Surescripts ePA**: Used for prescriber-initiated pharmacy benefit prior authorizations.

Humana Medical Policy Access and Utilization Management Criteria

Humana publishes its medical policies and coverage determinations on its provider website. For Medicare Advantage lines, which constitute a significant portion of Humana's enrollment, coverage policies must align with CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), ensuring that criteria are not more restrictive than Original Medicare.

Electronic Prior Authorization (ePA) and Da Vinci Project Alignment

Humana supports electronic prior authorization for various categories. Beyond X12 278 for medical benefits and CoverMyMeds/Surescripts for pharmacy benefits, Humana actively participates in the HL7 Da Vinci Project ecosystem. This engagement signals a commitment to advancing interoperability standards like Da Vinci PAS, CRD, and DTR for more streamlined electronic PA exchanges.

Prior Authorization Turnaround Times and CMS-0057-F Impact

Humana publishes precertification turnaround commitments on its provider site. For Medicare Advantage organization determinations, statutory timeframes traditionally allowed 14 calendar days for standard and 72 hours for expedited decisions. The CMS-0057-F rule, applicable to Humana's MA lines, tightens these to 7 calendar days for standard PA and 72 hours for expedited decisions for specific impacted-payer transaction categories, with phased compliance through 2027.

Common Denial Reasons and Appeal Pathways for Skyrizi with Humana

Denials for specialty drugs like Skyrizi can stem from insufficient documentation, lack of medical necessity, NCD/LCD non-coverage for MA lines, or failure to meet step therapy requirements. Humana returns denial reasons via X12 277/835 and portal updates. Medicare Advantage appeals follow a CMS-mandated 5-level structure, while commercial appeals adhere to distinct pathways documented in the provider manual.

Frequently asked questions

How does Humana process prior authorization for Skyrizi (risankizumab)?

Humana processes medical benefit prior authorizations for Skyrizi primarily through its Availity Essentials portal or via X12 278 transactions. If Skyrizi is covered under the pharmacy benefit, submissions route through CenterWell Specialty Pharmacy or ePA partners like CoverMyMeds/Surescripts.

Where can I find Humana's specific medical policies for Skyrizi?

Humana publishes its medical policies and coverage determinations on its provider website. For Medicare Advantage plans, these policies must align with applicable CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs).

What are the typical turnaround times for Humana Skyrizi prior authorizations?

Humana publishes its precertification turnaround commitments. For Medicare Advantage, standard prior authorizations are generally processed within 7 calendar days, and expedited requests within 72 hours, as per CMS-0057-F regulations impacting Humana.

What are common reasons for Skyrizi prior authorization denials from Humana?

Common denial reasons include insufficient documentation, lack of demonstrated medical necessity, non-adherence to step therapy protocols, or non-coverage under relevant NCDs/LCDs for Medicare Advantage plans.

Does Humana support electronic prior authorization (ePA) for Skyrizi?

Yes, Humana supports electronic PA. Medical benefit requests can be submitted via X12 278. Pharmacy benefit requests for Skyrizi can be routed through ePA platforms like CoverMyMeds/Surescripts or managed by CenterWell Specialty Pharmacy. Humana also participates in HL7 Da Vinci Project initiatives.